For example, it has been reported that drug carriers conjugated with targeting ligands, such as anti-Her2 antibody [8], folate [9], or transferrin (Tf) [10], have achieved therapeutic benefit by successfully targeting human epidermal receptors (HER), folate receptors, and transferrin receptor (TfR), respectively, all of which are overexpressed on tumor cells. The gene discussed is TF; the disease is neoplasm.